Cancer
Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer
June 3, 2019Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Japan’s health ministry warns of serious side effects of Lilly’s Verzenio
May 23, 2019Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma
Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …
Array Biopharma’s Braftovi triple therapy meets both endpoints in advanced colorectal cancer subtype
May 22, 2019Research and Development Array Biopharma, Braftovi, Cancer, colorectal cancer, pharma
Array Biopharma has revealed new data on its combination of Braftovi (encorafenib), Mektovi (binimetinib), and Erbitux (cetuximab), showing that it …
Amgen agrees to buy Nuevolution for $167 million
May 22, 2019Research and Development Amgen, Cancer, Nuevolution, biotech, drug discovery, immuno-oncology, immunology, pharma
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million). The …
MSD buys Peloton Therapeutics in deal worth $2.1 billion
May 22, 2019Research and Development Cancer, MSD, acquisition, biotech, deal, oncology, pharma
MSD has agreed to acquire all outstanding shares in Peloton Therapeutics in a deal worth up to $2.1 billion. US …
Children wait six and half years longer than adults for new cancer drugs, study says
May 22, 2019Research and Development Cancer, FDA, children, oncology, paediatrics, pharma
Children wait six and half years longer than adults to access new cancer drugs, according to a study from Dana-Farber/Boston …
Keytruda fails to improve overall survival in advanced triple-negative breast cancer
May 21, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer
MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …
AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit
May 20, 2019Research and Development, Sales and Marketing AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failure
AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed …
Phase 1/2 data show Roche’s entrectinib shrinks tumours with NTRK, ROS1 or ALK gene fusions in children & adolescents
May 17, 2019Medical Communications, Research and Development Cancer, Roche, entrectinib, pharma
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent …
Insider Interview: Paving paths in prostate cancer
May 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer
Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial
May 16, 2019Business Services, Research and Development Cancer, Immunogen, Shares, ovarian cancer, pharma, stocks
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 …
FDA greenlights Roche and AbbVie’s Venclexta for chronic lymphocytic leukaemia
May 16, 2019Sales and Marketing AbbVie, Cancer, FDA, Roche, Venclexta, leukaemia, pharma
Venclexta (venetoclax), the oral B-cell lymphoma-2 (BCL-2) inhibitor co-developed by AbbVie and Roche, has been approved by the FDA in …
MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma
May 14, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma
MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …
Latest content
ESTEVE CDMO adds $17.5m to Illinois expansion
Brenntag and dsm-firmenich expand biopharma vitamin partnership
